Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLC

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others

Enhancing breast cancer care through AI and collaboration